Centro de investigación en Salud Pública y Epidemiología Clínica (CISPEC). Facultad de Ciencias de la Salud "Eugenio Espejo", Universidad UTE, Quito, Ecuador.
Clinical Biostatistics Unit, Hospital Ramon y Cajal (IRYCIS), CIBER of Epidemiology and Public Health, Madrid, Spain.
BMC Complement Med Ther. 2020 Jan 15;20(1):12. doi: 10.1186/s12906-019-2803-2.
Although cannabis and cannabinoids are widely used with therapeutic purposes, their claimed efficacy is highly controversial. For this reason, medical cannabis use is a broad field of research that is rapidly expanding. Our objectives are to identify, characterize, appraise, and organize the current available evidence surrounding therapeutic use of cannabis and cannabinoids, using evidence maps.
We searched PubMed, EMBASE, The Cochrane Library and CINAHL, to identify systematic reviews (SRs) published from their inception up to December 2017. Two authors assessed eligibility and extracted data independently. We assessed methodological quality of the included SRs using the AMSTAR tool. To illustrate the extent of use of medical cannabis, we organized the results according to identified PICO questions using bubble plots corresponding to different clinical scenarios.
A total of 44 SRs published between 2001 and 2017 were included in this evidence mapping with data from 158 individual studies. We extracted 96 PICO questions in the following medical conditions: multiple sclerosis, movement disorders (e.g. Tourette Syndrome, Parkinson Disease), psychiatry conditions, Alzheimer disease, epilepsy, acute and chronic pain, cancer, neuropathic pain, symptoms related to cancer (e.g. emesis and anorexia related with chemotherapy), rheumatic disorders, HIV-related symptoms, glaucoma, and COPD. The evidence about these conditions is heterogeneous regarding the conclusions and the quality of the individual primary studies. The quality of the SRs was moderate to high according to AMSTAR scores.
Evidence on medical uses of cannabis is broad. However, due to methodological limitations, conclusions were weak in most of the assessed comparisons. Evidence mapping methodology is useful to perform an overview of available research, since it is possible to systematically describe the extent and distribution of evidence, and to organize scattered data.
尽管大麻和大麻素被广泛用于治疗目的,但它们的疗效却备受争议。因此,医用大麻的使用是一个快速发展的研究领域。我们的目标是使用证据图来识别、描述、评估和组织围绕大麻和大麻素治疗用途的现有证据。
我们检索了 PubMed、EMBASE、The Cochrane Library 和 CINAHL,以确定从成立到 2017 年 12 月发表的系统评价 (SR)。两位作者独立评估合格性并提取数据。我们使用 AMSTAR 工具评估纳入的 SR 的方法学质量。为了说明医用大麻的使用程度,我们根据确定的 PICO 问题,使用对应于不同临床情况的气泡图对结果进行组织。
共纳入 44 篇发表于 2001 年至 2017 年的 SR,其中包含来自 158 项单独研究的数据。我们在以下医疗条件中提取了 96 个 PICO 问题:多发性硬化症、运动障碍(如妥瑞氏症、帕金森病)、精神病状况、阿尔茨海默病、癫痫、急性和慢性疼痛、癌症、神经病理性疼痛、与癌症相关的症状(如与化疗相关的呕吐和厌食)、风湿性疾病、与 HIV 相关的症状、青光眼和 COPD。这些疾病的证据在结论和个别原始研究的质量方面存在差异。根据 AMSTAR 评分,SR 的质量为中等到高。
关于医用大麻使用的证据很广泛。然而,由于方法学上的限制,大多数评估比较的结论都很薄弱。证据图谱方法学对于进行现有研究的概述非常有用,因为它可以系统地描述证据的范围和分布,并组织分散的数据。